The patient has experienced any grade 3-4 gastrointestinal bleeding within 3 months prior to randomization
No history of gastrointestinal bleeding (GI) bleeding requiring a blood transfusion, endoscopic or operative intervention
Patients with intestinal obstruction or gastrointestinal bleeding
Patients with active bleeding are not eligible; specifically, no clinically significant gastrointestinal (GI) bleeding, GI perforation, intra-abdominal abscess or fistula for 6 months prior to enrollment, no hemoptysis or other signs of pulmonary hemorrhage for 3 months prior to enrollment; patients with evidence of an acute intracranial or intratumoral hemorrhage on CT or MRI are not eligible (patients with evidence of resolving hemorrhage will be eligible); in patients with CNS tumors, an MRI with ECHO gradient sequences would be required to exclude presence of petechial hemorrhages
Clinically significant bleeding event within the last 3 months, unrelated to trauma, or underlying condition that would be expected to result in a bleeding diathesis.
Patients with any grade 3-4 gastrointestinal bleeding within 3 months prior to enrollment
Significant GI or variceal bleeding or subdural hematoma within 3 months of the first dose of study drug
Patients with evidence of significant mucosal or internal bleeding
No clinically significant bleeding (i.e. gastrointestinal [GI] bleed, intracranial bleeding) within 6 months or major surgery within 4 weeks; minor surgeries (i.e. port placement, cataract surgery) are allowed within 2 weeks
Subject has an underlying condition predisposing them to bleeding or currently exhibits signs of clinically significant bleeding
Subject has a recent history of non-chemotherapy-induced thrombocytopenic-associated bleeding within 1 year prior to the first dose of study drug
Significant bleeding disorders within 6 months prior to administration of first dose of study drug, including but not limited to:\r\n* Hematemesis, hematochezia, melena or other gastrointestinal bleeding >= grade 2 (per CTCAE version 4.03)\r\n* Hemoptysis or other pulmonary bleeding >= grade 2 (per CTCAE version 4.03)\r\n* Hematuria or other genitourinary bleeding >= grade 2 (per CTCAE version 4.03)
Any grade 3-4 gastrointestinal (GI) bleeding within 3 months prior to enrollment
Bleeding and thrombosis:\r\n* Patients with evidence of active bleeding: intratumoral hemorrhage by current imaging, or bleeding diathesis are not eligible\r\n* Patients with known or prior history in prior 3 months of esophageal varices are not eligible\r\n* Patients with a history of CNS arterial/venous thromboembolic events including transient ischemic attack (TIA) or cerebrovascular accident (CVA) within 6 months prior to study enrollment are not eligible\r\n* Patients with a history of deep vein thrombosis (including pulmonary embolism) within 3 months prior to study enrollment are not eligible\r\n* Patients with a history of hemoptysis or other signs of pulmonary hemorrhage within 3 months prior to study enrollment are not eligible\r\n* Patients with a history of >= grade 3 bleeding disorders, vasculitis, or had a significant (>= grade 3) episode from the gastrointestinal bleeding, within 6 months prior to enrollment are not eligible\r\n* For part B: patients with CNS tumors and evidence of new CNS hemorrhage of more than punctate size and/or more than three foci of punctate hemorrhage on baseline magnetic resonance imaging (MRI) obtained within 14 days prior to study enrollment are not eligible; Note: echocardiogram (ECHO) gradient MRI sequences per institutional guidelines are required for patients with CNS tumors
Patients must not have a significant history of bleeding events\r\n* Patients with a history of a significant bleeding episode (e.g. hemoptysis, upper or lower gastrointestinal (GI) bleeding, grade 3 or 4 gross hematuria unable to be controlled by trans-urethral resection of the bladder tumor) within 6 months of registration are not eligible
The patient has uncontrolled or severe coagulopathies or a history of clinically significant bleeding within the past 6 months, such as hemoptysis, epistaxis, hematochezia, hematuria, or gastrointestinal bleeding.
History of major gastrointestinal bleeding within the last 3 months or any evidence of active gastrointestinal bleeding excludes the subject.
Active gastrointestinal bleeding within previous 2 months
Uncontrolled severe bleeding tendency or active gastrointestinal (GI) bleeding
The patient has any pre-existing coagulopathy, recent hemoptysis, gross hematuria, or gastrointestinal bleeding, and a history of a clinically significant cardiovascular or cerebrovascular event within 12 months prior to study entry
History of active gastrointestinal bleeding within 6 months prior to randomization.
Bleeding disorders or active significant bleeding (i.e. hemoptysis, hematochezia, hematemesis) within 3 weeks
For cohort 4, clinically significant hemorrhagic or ischemic stroke, including transient ischemic attacks and other central nervous system bleeding in the preceding 6 months that were not related to glioma surgery; history of prior intratumoral bleeding is not an exclusion criterion; however, patients with a history of prior intratumoral bleeding, will need to undergo a non-contrast head computed tomography (CT) to exclude acute bleeding
Has history of known coagulopathy that increases risk of bleeding or a history of clinically significant hemorrhage within 12 months of start of study drug
Patients with an underlying condition predisposing them to bleeding or currently exhibiting signs of clinically significant bleeding
Patients with a recent history of non-chemotherapy-induced thrombocytopenic-associated bleeding within 1 year prior to the first dose of study drug
Patients with major gastrointestinal bleeding in the prior 2 months of enrollment.
Uncontrolled or severe coagulopathies or a history of clinically-significant bleeding within the past 6 months, including any of the following, but not limited to:\r\n* Epistaxis\r\n* Hemoptysis\r\n* Hematochezia\r\n* Hematuria\r\n* Gastrointestinal bleeding\r\n* Spontaneous or tumor related intracranial hemorrhage
Prior history of clinically significant bleeding, intestinal obstruction, or GI perforation within 6 months of initiation of study treatment.
requirement for intravenous alimentation active gastrointestinal bleeding, unrelated to cancer, as evidenced by hematemesis, hematochezia, or melena in the past 3 months without evidence of resolution documented by endoscopy or colonoscopy.
Clinically significant bleeding within two weeks prior to randomization (e.g., gastrointestinal (GI) bleeding, intracranial hemorrhage)
Has history of known coagulopathy that increases risk of bleeding or a history of clinically significant hemorrhage within 12 months of registration
active gastrointestinal bleeding, unrelated to cancer, as evidenced by hematemesis, hematochezia or melena in the past 3 months without evidence of resolution documented by endoscopy or colonoscopy;
Has history bleeding disorders (e.g., pulmonary hemorrhage, significant hemoptysis, menometrorrhagia not responding to hormonal treatment) ? 2 months before C1D1
Grade 3 gastrointestinal (GI) bleeding within 3 months prior to screening
Patients with any major bleeding current or within the past 4 weeks. (e.g. recent gastrointestinal [GI] hemorrhage or neurosurgery).
Subjects who had a prior intracranial hemorrhage, known arteriovenous malformation or aneurysm, head trauma, or evidence of active bleeding;
Subjects who within 21 days prior to randomization have had gastrointestinal or genitourinary bleeding;
Patients with active bleeding are not eligible; specifically, no clinically significant gastrointestinal (GI) bleeding, GI perforation, intra-abdominal abscess or fistula for 6 months prior to enrollment, no hemoptysis or other signs of pulmonary hemorrhage for 3 months prior to enrollment
Patients with a history of gastrointestinal bleeding (GIB) within 6 weeks prior to registration are not eligible
Evidence or history of bleeding diathesis (greater than normal risk of bleeding, i.e., Hereditary Hemorrhagic Telangiectasia type I or HHT-1) or coagulopathy in the absence of therapeutic anti-coagulation or any hemorrhage/bleeding event > grade 3 within 4 weeks prior to registration; note: patients with full-dose anticoagulants are eligible provided the patient has been on a stable dose for at least 2 weeks of low molecular weight heparin; therapeutic Coumadin and aspirin doses > 325 mg daily are not allowed
Have a significant bleeding disorder or vasculitis or had a Grade ?3 bleeding episode within 12 weeks prior to enrollment.
Significant bleeding disorders within 6 months prior to administration of first dose of study drug, including but not limited to:\r\n* Hematemesis, hematochezia, melena or other gastrointestinal bleeding > grade 2 \r\n* Hemoptysis or other pulmonary bleeding > grade 2 \r\n* Hematuria or other genitourinary bleeding > grade 2
No abnormalities no history of ongoing or recent (less than or equal to 3 months of registration on protocol therapy) significant gastrointestinal bleeding
The patient has significant bleeding disorders, vasculitis, or experienced grade 3/4 gastrointestinal (GI) bleeding within 3 months prior to enrollment
Major bleeding within the last 6 months.
The patient has experienced any grade 3-4 gastrointestinal (GI) bleeding within 3 months prior to enrollment
No bleeding from gastrointestinal ulcers or other sites of bleeding
For subjects with CNS involvement (primary tumor or metastatic disease), have any active bleeding or new intratumoral hemorrhage of more than punctuate size of screening MRI obtained within 14 days of starting study drug or known bleeding diathesis or treatment with anti-platelet or anti-thrombotic agents
Patients with active hemoptysis, clinically significant non hemorrhoidal gastrointestinal (GI) bleeding or those with bleeding diathesis
Patients with evidence of recent intratumoral hemorrhage (within 3 months of study enrollment), gastrointestinal bleeding, history of coronary artery disease or on anticoagulation therapy
Subject has an underlying condition predisposing them to bleeding or currently exhibits signs of clinically significant bleeding
Subject has a recent history of non-chemotherapy-induced thrombocytopenic-associated bleeding within 1 year prior to the first dose of study drug
Patients with evidence of active bleeding, intratumoral hemorrhage or history of bleeding diatheses, unless specifically occurring as an isolated incident during reversible chemotherapy-induced thrombocytopenia
Clinically significant hemorrhagic or ischemic stroke, including transient ischemic attacks and other central nervous system bleeding in the preceding 6 months that were not related to glioma surgery; history of prior intratumoral bleeding is not an exclusion criteria; patients who with history of prior intratumoral bleeding, however, need to undergo a non-contrast head computed tomography (CT) to exclude acute bleeding
No warfarin therapy; low molecular weight heparin anticoagulation is permitted provided that patients have been clinically stable on anti-coagulation for at least 2 weeks prior to day 1 of study drug and meet platelet inclusion criteria; no history of active gastrointestinal (GI) bleeding or other major bleeding within previous 6 months prior to day 1 of study drug
Clinically significant bleeding event within the last 3 months, unrelated to trauma, or underlying condition that would be expected to result in a bleeding diathesis
Gastrointestinal bleeding within the past one year
Severe bleeding, hemoptysis, gastrointestinal hemorrhage, CNS bleeding, clinically significant hemorrhage or vaginal bleeding during the last 6 months
Lesions with underlying infection or clinically meaningful bleeding
For subjects with CNS involvement (primary tumor or metastatic disease): Subjects must not have any active bleeding, or new intratumoral hemorrhage of more than punctate size on screening MRI or known bleeding diathesis or treatment with anti-platelet or anti-thrombotic agents
Known portal hypertension or history of variceal bleeding
Underlying condition predisposing them to bleeding or currently exhibits signs of clinically significant bleeding
Recent history of non-chemotherapy-induced thrombocytopenic-associated bleeding =< 1 year prior to the registration
Subjects with history of known bleeding disorder(s) or history of clinically significant hemorrhage (e.g., gastrointestinal , neurologic), within the past 6 months.
Participants with history of known coagulopathy that increases risk of bleeding or a history of clinically significant hemorrhage within 12 months of start of study drug
Patients with an underlying condition predisposing them to bleeding or currently exhibiting signs of clinically significant bleeding
Patients with a recent history of non-chemotherapy-induced thrombocytopenic-associated bleeding within 1 year prior to the first dose of study drug
Grade 2 or higher ongoing gastrointestinal hemorrhage; patients with grade 1 gastrointestinal bleeding are eligible for participation
Patients with evidence of active bleeding, intratumoral hemorrhage or history of bleeding diatheses, unless specifically occurring as an isolated incident during reversible chemotherapy-induced thrombocytopenia
Uncontrolled hypertension, major bleeding, HIV infection, or recent acute\n             cardiovascular event
No history of abnormal bleeding tendency
No history of abnormal bleeding tendency or predisposition to repeated infections
For subjects with CNS involvement (primary tumor or metastatic disease): Have any active bleeding, or new intratumoral hemorrhage of more than punctate size on Screening MRI obtained within 14 days of starting study drug,or known bleeding diathesis or treatment with anti-platelet or anti-thrombotic agents
History of CNS bleeding within 6 months of registration
Patients with active bleeding of the GI tract or patients who have symptoms associated with stomach irritation (known as gastritis).
Patients who have experienced any grade 3-4 gastrointestinal (GI) bleeding within 3 months prior to first dose of protocol therapy
Have experienced a Grade ?3 bleeding event within 3 months (?3 months) prior to randomization.
Any history of clinically meaningful variceal bleeding within the last three months.
A history of bleeding (i.e., hemoptysis, hematuria, gastrointestinal blood loss, epistaxis, or others with greater than Grade 1 according to NCI CTCAE Version 4.03) within 1 month prior to beginning therapy or any clinical indications of current active bleeding.
Active GI bleeding, as evidenced by hematemesis, hematochezia or melena in the past 3 months without evidence of resolution documented by endoscopy or colonoscopy
History of major gastrointestinal bleeding within the last 6 months. Any evidence of active gastrointestinal bleeding excludes the subject.
Any significant bleeding (greater than or equal to grade 3, hemorrhage) that is not related to the primary colon tumor within 6 months before randomization.
Major upper gastrointestinal bleeding episode occurring during the previous year before screening.
Evidence of bleeding diathesis or clinically significant bleeding, within 28 days of C1D1 or history of hemoptysis of > 2.5 mL/1 teaspoon within 6 months of C1D1
A thrombotic or hemorrhagic event <=6 months prior to screening (includes hemoptysis, Gastrointestinal (GI) bleeding, hematemesis, central nervous system hemorrhage, epistaxis, vaginal bleeding, cerebral infarction, transient ischemic attacks, myocardial infarction, angina, and coronary artery disease)
have experienced any bleeding episode considered life-threatening, or any Grade 3 or 4 GI/variceal bleeding episode in the 3 months prior to enrollment requiring transfusion or endoscopic or operative intervention
Have significant bleeding disorders, vasculitis, or had a significant bleeding episode from the gastrointestinal tract within 12 weeks prior to randomization.
For patients that are to undergo the tumour biopsy, a history of a hereditary bleeding disorder, or clinically relevant major bleeding event in the past 6 months, as judged by the investigator.
Patients at risk of non-AML related major bleeding (e.g. recent gastrointestinal [GI] hemorrhage or neurosurgery).
History of gastrointestinal ulcer or bleeding within 3 months; any digestive tract dysfunction
Severe gastrointestinal bleeding within 12 weeks of treatment with G-202
Significant gastrointestinal bleeding within 6 weeks prior to consent.
History of active gastrointestinal (GI) bleeding or other major bleeding =< 12 months prior to randomization; Note: patients who do not have resolution of the predisposing risk factor (e.g., resection of a bleeding tumor, treatment and endoscopic documentation of a resolved ulcer) will also be excluded
History of major gastrointestinal bleeding within the last 6 months.
Has history of known coagulopathy that increases risk of bleeding or a history of clinically significant hemorrhage within 12 months of start of study drug
Subjects with a history of intestinal perforation, colitis, clinically significant gastrointestinal bleeding or intestinal obstruction within one year prior to enrollment.
Evidence of blood clotting or bleeding abnormalities
Subjects must not have clinically significant bleeding (i.e. gastrointestinal [GI] bleed, intracranial bleeding) within 6 months or have had major surgery within 4 weeks; minor surgeries (i.e. port placement, cataract surgery) are allowed if completed more than 2 weeks from the start of treatment
Have a history of or active significant gastrointestinal (GI) bleeding within 3 months of the first dose of brigatinib.
No patients with clinically significant gastrointestinal (GI) bleeding or bleeding diathesis within 30 days prior to registration
Has had significant bleeding/thrombosis in previous 4 weeks
History of clinically significant gastrointestinal (GI) bleeding within prior 2 months prior to enrollment
Presence of transfusion-dependent thrombocytopenia or a history of bleeding disorders or clinical conditions (e.g. gastrointestinal [GI] bleeding or constitutional disorders) that may increase risk of life-threatening bleeding when thrombocytopenic
Significant bleeding disorders within 6 months prior to administration of first dose of study drug, including but not limited to:\r\n* Hematemesis, hematochezia, melena or other gastrointestinal bleeding >= grade 2 (per CTCAE version 4.0)\r\n* Hemoptysis or other pulmonary bleeding >= grade 2 (per CTCAE version 4.0)\r\n* Hematuria or other genitourinary bleeding >= grade 2 (per CTCAE version 4.0)
Clinical significant gastrointestinal bleeding in the 6 months prior to Cycle 1 Day 1 (C1D1) first dose
History of major hemorrhage including gastrointestinal bleeding (grade 2-4), pulmonary hemorrhage, or clinically significant hemoptysis (> 1 teaspoon [tsp] in 24 hours) within the last 5 years; patients with underlying conditions that predispose to bleeding, such as bleeding diathesis, known esophageal varices, or tumor involving major vessels, are also excluded
Bleeding\r\n* Clinically significant bleeding, such as gross hematuria, gastrointestinal bleeding (excluding bleeding from rectal tumor), and hemoptysis within the 12 months before screening; if clinically significant bleeding has occurred within 12 months of screening but the cause has been identified and adequately treated (e.g., cystitis, ulcer), then this exclusion criterion does not apply\r\n* Minor biopsy-related bleeding lasting < 24 hours and resolved at least 1 week before Study Day 1 is allowed
History of bleeding (hemoptysis in excess of 2.5 mL or one-half teaspoon, hematuria, gastrointestinal [GI] blood loss, epistaxis, or others with greater than grade 1 according to Common Terminology Criteria for Adverse Events [CTCAE] version 4.0) within 1 month prior to beginning therapy or any clinical indications of current active bleeding
Clinically significant bleeding within 4 weeks of screening defined as any grade 3 or grade 4 bleeding by WHO Bleeding Scale or any gastrointestinal (GI) bleeding or intracranial hemorrhage
EXPANSION COHORT ONLY: Clinically significant gastrointestinal abnormalities that may increase the risk for GI bleeding including, but not limited to:\r\n* Activepeptic ulcer disease\r\n* Known intraluminal metastatic lesion/s with suspected bleeding\r\n* Inflammatory bowel disease \r\n* Ulcerative colitis, or other gastrointestinal conditions with increased risk of perforation
Clinically significant bleeding such as gross hematuria, gastrointestinal bleeding and hemoptysis within 6 months prior to enrollment.
History of severe gastrointestinal bleeding within 6 months; patients with gastrointestinal blood loss due to KS may be included
History of gastro-intestinal bleeding within 12 months
Recent history (within 1 year of first dose) of underlying, predisposing condition of bleeding or currently exhibits signs of bleeding
Subject has history of gastrointestinal ulcer or gastrointestinal bleeding within 3 months prior to the planned first dose of study drug.
Subject has active gastrointestinal ulcer or gastrointestinal bleeding within 3 months prior to the planned first dose of study drug.
No history of major bleeding, recent or active myocardial ischemia, gastrointestinal (GI) perforation, cerebrovascular accidents or other significant illness
Subject has a history of gastrointestinal bleeding within 90 days prior to the first dose of study drug.
No major surgery within 4 weeks prior to enrollment or history of gastrointestinal bleeding within 3 months prior to enrollment; no signs or symptoms of active bleeding or non-healing ulcer will be permitted at study entry; patients with central pulmonary tumors with evidence of bronchial invasion, or presenting with hemoptysis will be excluded
Active bleeding diathesis or history of any major bleeding (eg, requiring transfusion of red blood cells (RBCs), central nervous system (CNS) bleeding, or significant hemoptysis within 6 months of enrollment. Subjects with bleeding secondary to underlying disease (including gastrointestinal (GI) perforation or fistula) that has been corrected by surgery or alternative procedure may be included.
History of unexplained bleeding episodes within 3 months of M402 dosing
Current (significant or uncontrolled) gastrointestinal bleeding
Participants with a recent history (< 6 months) of a major bleed which will be defined as a symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with compartment syndrome, and/or bleeding causing a fall in hemoglobin level 2 grams/dL or more, or leading to transfusion of two or more units of whole blood or packed red cells
Prior treatment with a BTK inhibitor 19. Presence of transfusion-dependent thrombocytopenia or a history of bleeding disorders or clinical conditions (eg, gastrointestinal bleeding or constitutional disorders) that may increase risk of life-threatening bleeding when thrombocytopenic 20. History of stroke or intracranial hemorrhage within 6 months prior to signing the ICD 21. Medications that are strong inhibitors or inducers of CYP3A4/5 (eg, itraconazole, ketoconazole, clarithromycin, ritonavir, phenytoin, pentobarbital, and rifampin) should be changed; subjects who cannot change these medications must be excluded.
Have significant bleeding disorders, vasculitis, or had a significant bleeding episode from the gastrointestinal (GI) tract within 3 months prior to receiving study drugs.
History of gastrointestinal bleeding within the past 6 months
Participants with history of clinically significant bleeding, specifically any history of intracranial hemorrhage/hemorrhagic cardiovascular accident (CVA), or participants with gastrointestinal bleeding within the 12 months prior to study entry
Patients with acute gastrointestinal bleeding within 1 month of study entry
Has history of known coagulopathy that increases risk of bleeding or a history of clinically significant hemorrhage within 12 months of start of study drug.
Clinically significant bleeding such as gross hematuria, GI bleeding, and hemoptysis within the 6 months before screening
Patients are excluded with history of recent < 6 months thromboembolic events, clinically significant bleedingâ€”gross hematuria, hemoptysis, or gastrointestinal bleeding, history of bleeding diathesis or hypercoagulable state, or prior exposure to chimeric antibodies
Clinically significant gastrointestinal (GI) bleeding within 6 months prior to Cycle 1, Day 1
Patient has an underlying, predisposing condition of bleeding or currently exhibits signs of bleeding; the subject has a recent history of non-chemotherapy induced thrombocytopenic associated bleeding within 1 year prior to the first dose of study drug
Evidence or history of bleeding diathesis (greater than normal risk of bleeding, i.e., hereditary hemorrhagic telangiectasia type I or HHT-1) or coagulopathy in the absence of therapeutic anti-coagulation or any hemorrhage/bleeding event > grade 3 within 4 weeks prior to registration; note: patients with full-dose anticoagulants are eligible provided the patient has been on a stable dose for at least 2 weeks of low molecular weight heparin; therapeutic Coumadin and aspirin doses > 325 mg daily are not allowed
No gastrointestinal bleeding within 1 year of study entry.
Clinically significant gastrointestinal bleeding (bleeding requiring procedural intervention, eg. variceal banding, transjugular intrahepatic portosystemic shunt (TIPS) procedure, arterial embolization, topical coagulation therapy) within 6 months prior to first dose.
History of clinically significant gastrointestinal bleeding requiring procedural intervention (e.g., variceal banding, transjugular intrahepatic portosystemic shunt procedure, arterial embolization, topical coagulation therapy) within 4 weeks before enrollment.
Has experienced a Grade ? 3 bleeding event within 3 months prior to randomization
Experienced any serious Grade 3-4 gastrointestinal bleeding within 3 months prior to study entry
History of major thrombotic or clinically relevant major bleeding event in the past 6 months
Subject has history of gastrointestinal ulcer or gastrointestinal bleeding within 3 months prior to the first dose of study drug.
History of bleeding disorders or thrombotic events, e.g. hemorrhagic or thrombotic events within 12 months, clinically significant or tumor-related hemoptysis, active gastrointestinal bleeding or ulcers or major injuries or surgery
Subject has ? grade 2 bleeding at the time of randomization
Active grade >= 2 bleeding at the time of randomization, including hematuria
History of grade 4 bleeding
Patients at risk of non-disease related major bleeding (eg, recent GI hemorrhage or neurosurgery, within previous 21 days).
Persistent oral bleeding: > 15 mL (estimated) per day
History of intracranial bleeding at any time
Recent or ongoing clinically significant gastrointestinal disorder (e.g., malabsorption, bleeding, inflammation, emesis, diarrhea > grade 1)
Any bleeding episode considered life-threatening, or any Grade 3 or 4 gastrointestinal bleeding episode in the 3 months prior to randomization requiring intervention.
History of major bleeding (requiring a blood transfusion ? 2 units) not related to a tumor within the past 12 months
Recent acute bleeding requiring intervention in less than 24 hours
Gastrointestinal bleeding; note that the presence of any symptoms (dyspnea, fatigue, angina, weakness, malaise, melena, hematochezia, hematemesis, anemia, abdominal pain) will require clinical assessment to rule out gastrointestinal bleeding
Active bleeding or otherwise considered high risk for hemorrhage (e.g. known acute gastrointestinal ulcer)
Grade 3 or higher recent (within the past 6 months) or ongoing bleeding events
Participant has an underlying predisposition to gastrointestinal (GI) or rectal bleeding are considered ineligible for study participation
History of major bleeding with bronchoscopy
Major surgery or significant bleeding episodes within 28 days before study initiation\r\n* Major surgery does not include: breast or other biopsies obtained for diagnosis, placement of radio-opaque clip to localize a tumor or tumors for subsequent surgical resection, placement of central venous access, pretreatment lymph node sampling\r\n* Significant bleeding episodes are defined for the purpose of this study as hemoptysis or upper/lower gastrointestinal bleeding\r\n* Although bevacizumab will be administered in tracer quantities in this study and is not expected to have pharmacologic effects, participants with major surgery or significant bleeding episodes within 28 days before study initiation may be at a higher risk of bleeding
The patient has uncontrolled or severe coagulopathies or a history of clinically significant bleeding within the past 6 months, such as hemoptysis, epistaxis, hematochezia, hematuria, or gastrointestinal bleeding.
